Clark Asset Management Boosts Stake in Abbott Laboratories by 1,774 Shares

Clark Asset Management LLC has significantly increased its stake in Abbott Laboratories (NYSE: ABT), acquiring an additional 1,774 shares during the second quarter, raising its holdings by 78.1%. According to the firm’s latest 13F filing with the Securities and Exchange Commission (SEC), Clark now owns a total of 4,045 shares, valued at approximately $550,000.

The surge in Clark’s investment comes amid a broader trend among institutional investors. For instance, IMG Wealth Management Inc. expanded its position in Abbott Laboratories by an astonishing 759.1% during the same quarter. Following the purchase of 167 shares, IMG now holds 189 shares, valued at $26,000. Other firms, such as Hughes Financial Services LLC and Abound Financial LLC, also established new positions in the healthcare giant, with investments ranging from $27,000 to $33,000. Overall, institutional investors now own approximately 75.18% of Abbott’s stock.

Analyst Ratings and Stock Performance

Recent evaluations from research analysts highlight a generally positive outlook for Abbott Laboratories. On October 8, 2023, Weiss Ratings reaffirmed a “buy (b)” rating for the company’s shares. Subsequently, Royal Bank of Canada established an “outperform” rating, setting a price target of $147.00 on October 16. Barclays followed suit by increasing its target from $159.00 to $162.00 while maintaining an “overweight” rating.

As of October 17, two analysts rated Abbott’s stock as a Strong Buy, while seventeen issued Buy recommendations and four assigned a Hold rating. Data from MarketBeat indicates that Abbott Laboratories currently holds an average rating of “Moderate Buy” with a price target of $147.00.

On October 15, 2023, Abbott Laboratories reported its quarterly earnings, with earnings per share (EPS) reaching $1.30, matching analysts’ expectations. The company reported $11.37 billion in revenue, slightly below projections of $11.40 billion. Notably, Abbott’s revenue increased by 6.9% year-over-year, and the firm’s return on equity stood at 17.78%.

Dividends and Insider Transactions

In addition to its strong financial performance, Abbott Laboratories announced a quarterly dividend of $0.59 per share, to be paid on November 17, 2023, to shareholders recorded on October 15, 2023. This reflects an annualized dividend of $2.36 with a yield of 1.9%. The company’s dividend payout ratio is currently 29.57%.

In a separate development, Chief Financial Officer Philip P. Boudreau sold 5,550 shares of Abbott’s stock on August 8, 2023, at an average price of $134.55, totaling approximately $746,752.50. Post-sale, Boudreau holds 51,003 shares valued at about $6.86 million, indicating a 9.81% decrease in his position.

Abbott Laboratories is a global leader in healthcare products, operating through four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company’s diverse portfolio includes a range of solutions for various health conditions, underscoring its commitment to improving patient outcomes worldwide.